Lung Cancer Indicator Detection

Lung Cancer Clinical Trial

— LuCID  

Official title:

Lung Cancer Indicator Detection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02612532
• Other study ID #: LuCID-2
• Status: Completed
• Phase: N/A
• Start date: October 7, 2015
• Est. completion date: December 22, 2022

Study information

• Verified date: June 2023
• Source: Owlstone Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.

Description:

Rationale Approximately 75% of patients with lung cancer present with advanced disease. For those with stage 1 disease, the chance of cure is up to 70%. Therefore, diagnostics which may aid identification of those with early stage lung cancer will play an important role in future screening programs. Because all cancer cells are characterized by a change in their metabolism related to their uncontrolled growth, detection of the resulting metabolites may be a novel diagnostic tool for early stage lung cancer. Subsets of these metabolites are volatile and are exhaled as so-called volatile organic compounds (VOCs). Analysis of exhaled VOCs suggests they differ between patients with advanced lung cancer and healthy controls. The Lung Cancer Indicator Detection (LuCID) study aims to validate the use of a high-throughput breath analysis technique in a population of patients whom are clinically suspected of having lung cancer.

Methods LuCID is an international, multi-center case-control study. Patients referred by their GP or treating specialist for a diagnostic work-up for lung cancer will be invited to participate in the study. A maximum of two thousand five hundred patients whom consent to partake in this study will be asked to provide a breath sample prior to any diagnostic procedures. This is a non-invasive procedure that will require the patient to breath normally into a facemask to collect 2.5L of breath amounting to approximately 10 minutes of breathing. The resulting samples will be analyzed for VOCs by Gas Chromatography coupled to Mass Spectrometry and Gas Chromotography coupled to Field Assymetrical Ion Mobility Spectrometry. The resulting VOC profiles will be used to generate a diagnostic algorithm in order to try to differentiate between patients with and without lung cancer in the intention to diagnose population. This study will not interfere in any with the standard care offered at the clinical sites.

Outcomes The results of this study will provide detailed insights into the accuracy of the test for the detection of lung cancer in the intention to diagnose population. This will form the foundation for a subsequent study in a population at risk for the development of lung cancer. If sufficiently accurate for early stage disease, analysis of breath VOCs could help implement large-scale screening for lung cancer, significantly decreasing the morbidity and mortality of the disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2603
• Est. completion date: December 22, 2022
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Recruitment for these patients will be done from NHS hospitals whom identify or follow-up on patients suspected of having lung cancer.

• Inclusion criteria:

• Older than 18 years at time of consent

• Referred for investigation due to suspicion of lung cancer

• Referral based on suspicious symptoms

• Referral based on suspicious finding on imaging, including CTscan with indeterminate nodule requiring follow-up evaluation.

• Capable of understanding written and/or spoken language

• Able to provide informed consent

• Exclusion criteria:

• (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypo-ventilation, respiratory failure or claustrophobia when wearing the sampling mask

• Participating in a Clinical Trial Investigational Medicinal Product (CTIMP)

• Pulmonary function test with metacholine or beta-2-sympatico mimetic in last 2 hours.

• Any lung biopsy in the past 48 hours

• Currently undergoing anti-cancer treatment for lung cancer

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• ReCIVA breath sampler
Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva

Locations

Country	Name	City	State
Belgium	UZA University Hospital Antwerp	Antwerp
Belgium	UZG University Hospital Gent	Gent
Germany	University Hospital Leipzig	Leipzig
Italy	University Hospital Bari	Bari
United Kingdom	Wycombe	Buckingham
United Kingdom	PapworthHospital	Cambridge	Cambridgeshire
United Kingdom	University Hospital of Leicester	Leicester
United Kingdom	University Hospital Aintree NHS Foundation Trust	Liverpool
United Kingdom	University College London	London
United Kingdom	Watford Hospital NHS Trust	London
United Kingdom	University Hospital of South Manchester NHs Foundation Trust	Manchester
United Kingdom	Nottingham University Hospital NHS Trust	Nottingham
United Kingdom	Peterborough and Stamford Hospital	Peterborough
United Kingdom	South Tyneside District Hospital	South Shields
United Kingdom	Southampton General Hospital	Southampton
United Kingdom	Royal Stoke University Hospital NHS Trust	Stoke
United Kingdom	Wirral University Teaching Hospital NHS Foundation Trust	Upton

Sponsors (21)

Lead Sponsor

Collaborator

Owlstone Ltd

Barnet and Chase Farm Hospitals NHS Trust, Buckinghamshire Healthcare NHS Trust, Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK), Glenfield Hospital, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, Manchester University NHS Foundation Trust, Papworth Hospital NHS Foundation Trust, Peterborough and Stamford Hospitals NHS Foundation Trust, South Tyneside and Sunderland NHS Foundation Trust, Universitätsklinikum Leipzig, University College, London, University Hospital Southampton NHS Foundation Trust, University Hospital, Antwerp, University Hospital, Ghent, University Hospitals of North Midlands NHS Trust, University Hospitals, Leicester, University of Athens, University of Bari, Wirral University Teaching Hospital NHS Trust

Countries where clinical trial is conducted

Belgium,  Germany,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.	Diagnostic accuracy of VOC analysis for Lung Cancer diagnosis based on pattern recognition analysis of raw VOC-spectra generated by Lonestar analysis of breath.	2 years
Secondary	Fraction of within group variability in exhaled VOCs explained by factors not primarily related to disease proces	Assessment of potential parameters affecting exhaled VOCs other than lung cancer such as smoking, diet and co-morbidities	2 years
Secondary	Identified exhaled biomarkers associated with tumor stage and size.	Analysis of correlation between exhaled biomarkers and the type, stage and size of the pulmonary tumor.	2 years

External Links

•   LuCID study homepage